JP2023523869A5 - - Google Patents
Info
- Publication number
- JP2023523869A5 JP2023523869A5 JP2023509466A JP2023509466A JP2023523869A5 JP 2023523869 A5 JP2023523869 A5 JP 2023523869A5 JP 2023509466 A JP2023509466 A JP 2023509466A JP 2023509466 A JP2023509466 A JP 2023509466A JP 2023523869 A5 JP2023523869 A5 JP 2023523869A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063016247P | 2020-04-27 | 2020-04-27 | |
| US63/016,247 | 2020-04-27 | ||
| PCT/US2021/029315 WO2021222188A1 (en) | 2020-04-27 | 2021-04-27 | Anti-cd40 antibody combination treatment for cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523869A JP2023523869A (ja) | 2023-06-07 |
| JPWO2021222188A5 JPWO2021222188A5 (https=) | 2024-05-13 |
| JP2023523869A5 true JP2023523869A5 (https=) | 2024-05-13 |
Family
ID=76035114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509466A Pending JP2023523869A (ja) | 2020-04-27 | 2021-04-27 | がんのための抗ｃｄ４０抗体併用治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230203175A1 (https=) |
| EP (1) | EP4143230A1 (https=) |
| JP (1) | JP2023523869A (https=) |
| KR (1) | KR20230003081A (https=) |
| CN (1) | CN115667311A (https=) |
| AU (1) | AU2021262745A1 (https=) |
| BR (1) | BR112022021641A2 (https=) |
| CA (1) | CA3176974A1 (https=) |
| IL (1) | IL297657A (https=) |
| MX (1) | MX2022013557A (https=) |
| TW (1) | TW202206100A (https=) |
| WO (1) | WO2021222188A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4377348A1 (en) * | 2021-07-30 | 2024-06-05 | Seagen Inc. | Treatment for cancer |
| JP2025521028A (ja) * | 2022-06-23 | 2025-07-04 | アリゲーター・バイオサイエンス・アーベー | 併用療法 |
| WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CA2609269C (en) | 2005-05-26 | 2014-08-05 | Seattle Genetics, Inc. | Humanized anti-cd40 antibodies and their methods of use |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| US8163551B2 (en) | 2008-05-02 | 2012-04-24 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| CA2963720C (en) | 2014-10-29 | 2024-05-14 | Seattle Genetics, Inc. | Dosage and administration of non-fucosylated anti-cd40 antibodies |
-
2021
- 2021-04-26 TW TW110114992A patent/TW202206100A/zh unknown
- 2021-04-27 CA CA3176974A patent/CA3176974A1/en active Pending
- 2021-04-27 WO PCT/US2021/029315 patent/WO2021222188A1/en not_active Ceased
- 2021-04-27 US US17/921,521 patent/US20230203175A1/en active Pending
- 2021-04-27 KR KR1020227041425A patent/KR20230003081A/ko active Pending
- 2021-04-27 IL IL297657A patent/IL297657A/en unknown
- 2021-04-27 EP EP21727017.2A patent/EP4143230A1/en not_active Withdrawn
- 2021-04-27 MX MX2022013557A patent/MX2022013557A/es unknown
- 2021-04-27 JP JP2023509466A patent/JP2023523869A/ja active Pending
- 2021-04-27 CN CN202180039219.0A patent/CN115667311A/zh active Pending
- 2021-04-27 BR BR112022021641A patent/BR112022021641A2/pt unknown
- 2021-04-27 AU AU2021262745A patent/AU2021262745A1/en not_active Abandoned